eliquis apixaban eliquis apixaban eliquis apixaban logo

This information is intended for healthcare professionals based in the UK.

If you are not a healthcare professional in the UK, please click here.

For Prescribing and Adverse Event reporting information, click here.

desk-img mob-img


In AVERROES, ELIQUIS (apixaban) demonstrated superior stroke / systemic embolism prevention with a comparable rate of major bleeding vs. aspirin in patients with NVAF considered unsuitable for warfarin1,2*†‡

§ 94% of ELIQUIS patients received a 5 mg BD dose.1 A 2.5 mg BD dose was used in a subset of ELIQUIS patients (6%) who met two or more of the following criteria: ≥80 years, body weight ≤60 kg, or serum creatinine ≥1.5 mg/dl (133 µmol/l).1 Patients with the exclusive criteria of severe renal impairment (creatinine clearance 15–29 ml/min) should also receive a lower dose of 2.5 mg twice daily.2


ELIQUIS 5 mg BD: simple dosing for stroke prevention in NVAF, with or without food

It’s simple to switch your patients to ELIQUIS2

View the latest AF treatment guidelines

Purple information icon ELIQUIS (apixaban) SmPC

Please click here to access the ELIQUIS SmPC.

Purple information icon ELIQUIS (apixaban) Patient Information Leaflet

Please click here to access the ELIQUIS Patient Information Leaflet.

AVERROES = Apixaban Versus Acetylsalicylic Acid [ASA] to Prevent Stroke in Atrial Fibrillation Patients Who Have Failed or Are Unsuitable for Vitamin K Antagonist Treatment   
AF = Atrial Fibrillation   
ARR = Absolute Risk Reduction   
BD = Twice Daily   
CI = Confidence Interval   
HR = Hazard Ratio   
N = Total number of patients in either the ELIQUIS group or the aspirin group   
n = Number of patients with event   
NOAC = Non-vitamin K antagonist Oral Anticoagulant   
NVAF = Non-Valvular Atrial Fibrillation   
RRR = Relative Risk Reduction   
TIA = Transient Ischaemic Attack   
VKA = Vitamin K Antagonist

* In the AVERROES study, a total of 5,598 patients considered to be unsuitable for VKA by the investigators were randomised to treatment with ELIQUIS 5 mg BD (or 2.5 mg BD in selected patients [6.4%]) or aspirin. Aspirin was given once-daily at a dose of 81 mg (64%), 162 (26.9%), 243 (2.1%), or 324 mg (6.6%) at the discretion of the investigator.2

Assessed by sequential testing strategy designed to control the overall type I error in the trial.2

Common reasons for unsuitability for VKA therapy in the AVERROES trial included unable / unlikely to obtain INRs at requested intervals (42.6%), patient refused treatment with VKA (37.4%), CHADS2 score = 1 and physician did not recommend VKA (21.3%), patient could not be relied on to adhere to VKA medication instruction (15.0%), and difficulty / expected difficulty in contacting patient in case of urgent dose change (11.7%).2


  1. Connolly SJ et al. N Engl J Med 2011; 364: 806–817.
  2. ELIQUIS® (apixaban) Summary of Product Characteristics.